

Having described the invention, what is claimed is:

1. A method of treating a HIV comprising of:
the use of at least one polypeptide including an amino acid sequence from the group consisting of KPV, MEHFRWG, HFRWGKPV, SYSMEHFRWGKPV or a biologically functional equivalent of any of the foregoing.
2. The method of claim 1 wherein the HIV is accompanied by the presence of bacteria or fungi or both.
3. The method of claim 2 wherein the bacteria present is from the genus *Staphylococcus*.
4. The method of claim 2 wherein the bacteria present is *Staphylococcus aureus*.
5. The method of claim 2 wherein the fungi present is from the genus *Candida*.
6. The method of claim 2 wherein the fungi present is *Candida albicans*.
7. The method of claim 1 wherein the amino acid sequence KPV, HFRWGKPV, or SYSMEHFRWGKPV is located at the C-terminal of at least one polypeptide.
8. The method of claim 1 wherein the amino acid sequences KPV, HFRWGKPV, MEHFRWG, or SYSMEHFRWGKPV includes at least one amino acid in the D-form.
9. The method of claim 1 wherein at least one polypeptide is N-acetylated or C-amidated or both.
10. The method of claim 1 wherein the at least one polypeptide includes a dimer from any amino acid sequence in the group in claim 1.
11. The method of claim 2 wherein the dimer is a KPV dimer.
12. A method of treating a HIV comprising of:
Att 12/7

the use of at least one polypeptide including an amino acid sequence from the group consisting of KPV, MEHFRWG, HFRWGKPV, SYSMEHFRWGKPV or a biologically functional equivalent of any of the foregoing in a pharmaceutically appropriate amount contained in one of the carriers from the following group consisting of a solution for injection, a liquid, a pill, a capsule, a suppository, and an inhaler.

5 13. A method of treating secondary infections in persons with HIV comprising:

Sub 9/12
10 the use of at least one polypeptide including an amino acid sequence from the group consisting of KPV, MEHFRWG, HFRWGKPV, SYSMEHFRWGKPV or a biologically functional equivalent of any of the foregoing in a pharmaceutically appropriate amount contained in one of the carriers from the following group consisting of a solution for injection, a liquid, a pill, a capsule, a cream, an ointment, a gel, a suppository, an aerosol spray, and an inhaler.

15 14. A method of treating a inflammation due to HIV and/or secondary infections comprising of:

the use of at least one polypeptide including an amino acid sequence from the group consisting of KPV, MEHFRWG, HFRWGKPV, SYSMEHFRWGKPV or a biologically functional equivalent of any of the foregoing.

20

Add 927
add 05